Related Experiment Video
Updated: Dec 23, 2025
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
Recent Progress of Potentiating Immune Checkpoint Blockade with External Stimuli-an Industry Perspective
Jun Xu1, Robert Saklatvala2, Sachin Mittal1
1Sterile and Specialty Products MRL Merck & Co., Inc. 2000 Galloping Hill Rd Kenilworth NJ 07033 USA.
Abstract:
The past decade has seen the materialization of immune checkpoint blockade as an emerging approach to cancer treatment. However, the overall response and patient survival are still modest. Various efforts to study the "cancer immunogram" have highlighted complex biology that necessitates a multipronged approach. This includes increasing the antigenicity of the tumor, strengthening the immune infiltration in the tumor microenvironment, removing the immunosuppressive mechanisms, and reducing immune cell exhaustion. The coordination of these approaches, as well as the ability to enhance them through delivery, is evaluated. Due to their success in multiple preclinical models, external-stimuli-responsive nanoparticles have received tremendous attention. Several studies report success in distantly located tumor regression, metastases, and reoccurrence in preclinical mouse models. However, clinical translation in this space remains low. Herein, the recent advancement in external-stimuli-responsive nanoconstruct-synergized immune checkpoint blockade is summarized, offering an industry perspective on the limitations of current academic innovations and discussing challenges in translation from a technical, manufacturing, and regulatory perspective. These limitations and challenges will need to be addressed to establish external-stimuli-based therapeutic strategies for patients.
Insights
External-stimuli-responsive nanoparticles show promise in enhancing cancer immunotherapy by targeting the tumor microenvironment. However, clinical translation of these nanoconstructs faces significant technical and regulatory hurdles.
Area of Science:
- Oncology
- Nanotechnology
- Immunotherapy
Background:
- Immune checkpoint blockade (ICB) is a key cancer therapy, but modest response rates necessitate improved strategies.
- The complex "cancer immunogram" requires a multipronged approach to enhance anti-tumor immunity.
- External-stimuli-responsive nanoparticles offer a promising platform for synergistic cancer treatment.
Purpose of the Study:
- To summarize recent advancements in external-stimuli-responsive nanoconstructs combined with immune checkpoint blockade.
- To provide an industry perspective on the limitations of current academic innovations in this field.
- To discuss challenges hindering the clinical translation of these therapeutic strategies.
Main Methods:
- Review of preclinical studies on external-stimuli-responsive nanoparticles in cancer models.
- Analysis of strategies to enhance tumor antigenicity, immune infiltration, and overcome immunosuppression.
- Evaluation of nanoparticle delivery systems for synergistic effects with immune checkpoint blockade.
Main Results:
- Preclinical models show success in tumor regression, metastasis control, and preventing recurrence using these nanoconstructs.
- Significant gap exists between academic research findings and clinical application.
- Nanoparticle-based approaches demonstrate potential to overcome limitations of current immunotherapies.
Conclusions:
- External-stimuli-responsive nanoconstructs hold potential to synergize with immune checkpoint blockade for improved cancer treatment.
- Clinical translation is hampered by technical, manufacturing, and regulatory challenges.
- Addressing these limitations is crucial for developing effective nanotherapeutic strategies for patients.
